Skip to content
Invest now

Redefining the standard of care for solid tumors

Therapeutic Areas

For every cancer patient who responds to today’s treatment options, countless don’t. Our goal with AAV immuno-gene therapy is for robust treatment response to be the rule, not the exception. And we’re starting with brain cancers.

Why start with brain cancers?

These are notoriously difficult-to-treat cancers and often carry a devastating prognosis. The unmet need for patients with these cancers is dire.

The opportunity for Siren to help is massive.

Attempts to effectively treat brain cancers with systemic drugs have largely failed. Systemic drugs can’t cross the blood brain barrier and get to the tumor site. They are too toxic, and they are generally ineffective against these tumors.

The brain’s immune-privileged status allows us to locally deliver AAV without excluding patients based on neutralizing antibodies. AAV has already proven it can deliver transformative clinical results in the brain, underscoring its potential for treating brain tumors.

Our combination of AAV cytokine vectorization and direct tumor-targeting makes our approach ideally suited for brain cancers.

Introducing SRN-101, a universal AAV immuno-gene therapy drug product

Our first clinical program with SRN-101 will target high-grade gliomas, aggressive brain cancers with limited therapeutic options

Validated Payload

SRN-101 is a recombinant adeno-associated virus vector expressing an engineered cytokine payload with clinically validated immunomodulatory and antineoplastic effects

Regulatory Designations

The FDA has granted Orphan Drug and Rare Pediatric Disease Designations for SRN-101 for high-grade gliomas and pediatric-type diffuse high-grade gliomas, respectively

Leading the Way

High-grade gliomas are just the start; SRN-101’s promise extends to numerous solid tumor cancers